| Chinese abstract | 第1-8页 |
| English abstract | 第8-17页 |
| INTRODUCTION | 第17-25页 |
| Genetic hallmark of CML | 第17-18页 |
| Conventional approaches in CML treatment | 第18-19页 |
| Bcr/Abl features | 第19页 |
| Mechanisms of action of STI571 | 第19页 |
| Clinical efficacy of Gleevec (STI571)-treatment in CML | 第19-20页 |
| Mechanisms of STI571 resistance | 第20-21页 |
| Significance of STI571 development and future directions in CML treatment | 第21-22页 |
| Reference | 第22-25页 |
| CHAPTER Ⅰ MEK1/2 INHIBITORS INTERACT SYNERGISTICALLY WITH STI571 TO INDUCE APOPTOSIS IN BCR/ABL-EXPRESSING HUMAN LEUKEMIA CELLS | 第25-57页 |
| INTRODUCTION | 第25-27页 |
| MATERIALS AND METHODS | 第27-31页 |
| RESULTS | 第31-46页 |
| DISCUSSION | 第46-50页 |
| REFERENCES | 第50-57页 |
| CHAPTER Ⅱ HISTONE DEACETYLASE INHIBITORS PROMOTE STI571-MEDIATED APOPTOSIS IN BCR/ABL POSITIVE HUMAN MYELOID LEUKEMIA CELLS | 第57-83页 |
| INTRODUCTION | 第57-58页 |
| MATERIALS AND METHODS | 第58-62页 |
| RESULTS | 第62-72页 |
| DISCUSSION | 第72-76页 |
| REFERENCES | 第76-83页 |
| CHAPTER Ⅲ THE PROTEASOME INHIBITOR PS-341 INTERACTS SYNERGISTICALLY WITH HISTONE DEACETYLASE INHIBITORS TO INDUCE APOPTOSIS IN BCR/ABL~+ CELLS SENSITIVE AND RESISTANT TO STI571 | 第83-109页 |
| INTRODUCTION | 第83-84页 |
| MATERIALS AND METHODS | 第84-88页 |
| RESULTS | 第88-100页 |
| DISCUSSION | 第100-103页 |
| REFERENCES | 第103-109页 |
| CHAPTER Ⅳ INHIBITION OF THE PI3K PATHWAY SENSITIZES FLUDARABINE-INDUCED APOPTOSIS IN HUMAN LEUKEMIC CELLS THROUGH AN INACTIVATION OF MAPK-DEPENDENT PATHWAY | 第109-122页 |
| INTRODUCTION | 第109-110页 |
| MATERIALS AND METHODS | 第110-112页 |
| RESULTS AND DISCUSSION | 第112-119页 |
| REFERENCES | 第119-122页 |
| DISCUSSION | 第122-133页 |
| References | 第127-133页 |
| NOVELTY | 第133-135页 |
| 2003-2005 MAIN PUBLICATIONS | 第135-137页 |
| ACKNOWLEDGEMENT | 第137-138页 |
